Provention Bio, Inc. (PRVB) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

RED BANK, N.J., May 3, 2021 /PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB) (the “Company”), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today ...

RED BANK, N.J., July 29, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it ...

Tourlite Capital Management, an investment management company, released its fourth-quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, Tourlite Fund Founder ...

Provention Bio Inc (NASDAQ:PRVB) shares are trading higher by 20.6% to $5.97 Thursday morning after the company announced it has entered into a co-promotion agreement with Sanofi U.S. for the launch ...

LEBANON, N.J. and BOSTON, July 18, 2017 /PRNewswire/ -- Provention Bio, Inc., a clinical stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed ...

Shares of Provention Bio Inc. were down 3.9% in trading on Friday morning, the day after the Food and Drug Administration approved the company's treatment that can delay the onset of Type 1 diabetes ...

Good morning, everyone. My name is Jamie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Provention Bio call. [Operator Instructions] Please be ...

Provention Bio, Inc. (PRVB) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.56 per share a year ago. These figures ...

RED BANK, N.J., May 3, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today ...